Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 20/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823518 | 0.99 | CXCR4 (1.00) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL1878773 | 0.99 | CXCR4 (1.00) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| Bromide SCHEMBL5140353 | 0.93 | CXCR4 (0.86) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5140052 | 0.93 | CXCR4 (0.86) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5140576 | 0.93 | CXCR4 (0.85) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL14129578 | 0.93 | CXCR4 (0.88) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL4069667 | 0.93 | CXCR4 (0.88) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL13909515 | 0.93 | CXCR4 (0.88) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL28446985 | 0.93 | CXCR4 (0.88) | CXCR4CYP2D6CYP3A4CHRM2DRD2 | |
| SCHEMBL4063485 | 0.92 | CXCR4 (0.87) | CXCR4CYP2D6CHRM2DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629337-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264434-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | CHRM2 291/4885CXCR4 2/4885CYP2D6 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.